Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Overview of attention for article published in Clinical Cancer Research, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 60 tweets from 51 users, with an upper bound of 250,628 followers.

RT @DrEzraCohen: Goal of neoadjuvant immunotherapy must be pCR and this is most likely in tumors with moderate to high PDL1 expression. Thi…

RT @DrEzraCohen: Goal of neoadjuvant immunotherapy must be pCR and this is most likely in tumors with moderate to high PDL1 expression. Thi…

RT @AnwaarSaeed3: Negative neoadjuvant pembro + chemorad study in GEJ. Again here, PD-L1 CPS matters ✨ https://t.co/Y7J8b7FW53

RT @DrEzraCohen: Goal of neoadjuvant immunotherapy must be pCR and this is most likely in tumors with moderate to high PDL1 expression. Thi…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 56 additional tweets.